AU2017225495B2 - Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment - Google Patents

Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment Download PDF

Info

Publication number
AU2017225495B2
AU2017225495B2 AU2017225495A AU2017225495A AU2017225495B2 AU 2017225495 B2 AU2017225495 B2 AU 2017225495B2 AU 2017225495 A AU2017225495 A AU 2017225495A AU 2017225495 A AU2017225495 A AU 2017225495A AU 2017225495 B2 AU2017225495 B2 AU 2017225495B2
Authority
AU
Australia
Prior art keywords
ser
val
leu
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017225495A
Other languages
English (en)
Other versions
AU2017225495A1 (en
Inventor
Caroline Mary
Nicolas Poirier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSE Immunotherapeutics SA
Original Assignee
OSE Immunotherapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSE Immunotherapeutics SA filed Critical OSE Immunotherapeutics SA
Publication of AU2017225495A1 publication Critical patent/AU2017225495A1/en
Application granted granted Critical
Publication of AU2017225495B2 publication Critical patent/AU2017225495B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017225495A 2016-02-29 2017-02-28 Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment Active AU2017225495B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301271P 2016-02-29 2016-02-29
US62/301,271 2016-02-29
PCT/IB2017/000293 WO2017149394A1 (en) 2016-02-29 2017-02-28 Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment

Publications (2)

Publication Number Publication Date
AU2017225495A1 AU2017225495A1 (en) 2018-08-23
AU2017225495B2 true AU2017225495B2 (en) 2024-05-09

Family

ID=58530580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017225495A Active AU2017225495B2 (en) 2016-02-29 2017-02-28 Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment

Country Status (22)

Country Link
US (1) US11230602B2 (enExample)
EP (1) EP3423496B1 (enExample)
JP (1) JP7053479B2 (enExample)
KR (1) KR102819051B1 (enExample)
CN (1) CN109195987B (enExample)
AU (1) AU2017225495B2 (enExample)
CY (1) CY1122072T1 (enExample)
DK (1) DK3423496T3 (enExample)
ES (1) ES2737307T3 (enExample)
HR (1) HRP20191445T1 (enExample)
HU (1) HUE045183T2 (enExample)
IL (1) IL261330B2 (enExample)
LT (1) LT3423496T (enExample)
MA (1) MA43767B1 (enExample)
MD (1) MD3423496T2 (enExample)
ME (1) ME03446B (enExample)
PL (1) PL3423496T3 (enExample)
PT (1) PT3423496T (enExample)
RS (1) RS59223B1 (enExample)
SI (1) SI3423496T1 (enExample)
SM (1) SMT201900460T1 (enExample)
WO (1) WO2017149394A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
US12258577B2 (en) 2017-08-29 2025-03-25 Ose Immunotherapeutics Method effector cells using anti-CD127 antibodies for applications in cell therapy
KR20240056644A (ko) * 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
CN114746445A (zh) * 2019-06-28 2022-07-12 墨尔本大学 抑制或激活γδT细胞的方法
WO2021105988A1 (en) 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
AU2021262748A1 (en) 2020-04-27 2022-12-01 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting CD127 and use thereof
WO2021236691A1 (en) * 2020-05-18 2021-11-25 Jumaa Weinacht Hassan Composition for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056984A1 (en) * 2011-10-19 2013-04-25 Effimune Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ES2686593T3 (es) 2006-05-31 2018-10-18 The Regents Of The University Of California Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
CA2787070A1 (en) 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056984A1 (en) * 2011-10-19 2013-04-25 Effimune Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer

Also Published As

Publication number Publication date
KR102819051B1 (ko) 2025-06-12
CN109195987A (zh) 2019-01-11
PT3423496T (pt) 2019-09-05
CA3014313A1 (en) 2017-09-08
EP3423496A1 (en) 2019-01-09
CN109195987B (zh) 2022-05-27
IL261330B (en) 2022-11-01
JP7053479B2 (ja) 2022-04-12
HUE045183T2 (hu) 2019-12-30
MA43767A (fr) 2019-01-09
SI3423496T1 (sl) 2019-10-30
WO2017149394A1 (en) 2017-09-08
RS59223B1 (sr) 2019-10-31
CY1122072T1 (el) 2020-11-25
MA43767B1 (fr) 2019-08-30
US11230602B2 (en) 2022-01-25
PL3423496T3 (pl) 2020-01-31
ME03446B (me) 2020-01-20
HRP20191445T1 (hr) 2019-11-15
AU2017225495A1 (en) 2018-08-23
DK3423496T3 (da) 2019-08-19
JP2019515648A (ja) 2019-06-13
SMT201900460T1 (it) 2019-09-09
IL261330A (en) 2018-10-31
BR112018067479A2 (pt) 2019-01-15
KR20180118746A (ko) 2018-10-31
MD3423496T2 (ro) 2020-01-31
ES2737307T3 (es) 2020-01-13
IL261330B2 (en) 2023-03-01
US20200308288A1 (en) 2020-10-01
LT3423496T (lt) 2019-09-25
EP3423496B1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
AU2022201144B2 (en) Antigen binding molecules comprising a TNF family ligand trimer
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
RU2753902C2 (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
KR102916159B1 (ko) Ilt4에 결합하는 항체
CN109195987B (zh) 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用
CN107001472B (zh) 对cd73具有特异性的结合分子及其用途
AU2020316495B2 (en) Humanized anti-VEGF Fab antibody fragment and use thereof
CN109689688B (zh) 抗icos抗体
AU2017206074B2 (en) Tetravalent anti-PSGL-1 antibodies and uses thereof
CN112566935A (zh) 抗ox40抗体和使用方法
KR20200002889A (ko) Ox40 및 ctla-4에 대한 이중특이적 항체
AU2017297506A1 (en) Antibodies against TIM3 and uses thereof
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20230038311A (ko) 항-cd73 항체와의 조합 요법
KR102724790B1 (ko) 항 cd147 항체
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20100021601A (ko) 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
TW201249870A (en) Novel immunoconjugates
KR20230125855A (ko) Cd73에 대항한 항체 및 그의 용도
AU2020316498B2 (en) Humanized anti-VEGF monoclonal antibody
TW202313110A (zh) 癌症之治療
TW202309089A (zh) 抗體
HK40109194A (en) Antibodies
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer
HK40050839A (en) Anti-ox40 antibodies and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)